Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus CEFOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus CEFOBID.
CEFEPIME IN PLASTIC CONTAINER vs CEFOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
None Documented
None Documented
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
2 hours (prolonged in hepatic impairment and neonates).
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic